The relationship between PLOD1 expression level and glioma prognosis investigated using public databases.

Background: Glioma is the most common type of intracranial tumor with high malignancy and poor prognosis despite the use of various aggressive treatments. Targeted therapy and immunotherapy are not effective and new biomarkers need to be explored. Some Procollagen-lysine 2-oxyglutarate 5-dioxygenase () family members have been found to be involved in the metastasis and progression of tumors. Both and had been reported to be highly expressed in gliomas, while the prognostic value of remains to be further illustrated, so we want to investigate the expression in glioma and its clinical implication.

Methods: We collected gene expression and corresponding clinical data of glioma from the Chinese Glioma Genome Atlas (CGGA) database, The Cancer Genome Atlas (TCGA) database and the Gene Expression Omnibus (GEO) database. First, we analyzed the expression and mutation of in gliomas and its relationship with clinicopathologic characteristics. Then, we conducted survival analysis, prognostic analysis and nomogram construction of the gene. Finally, we conducted gene ontology (GO) enrichment analysis and gene set enrichment analysis (GSEA) to explore possible mechanisms and gene co-expression analysis was also be performed.

Results: The results showed that the expression level of was higher in gliomas than normal tissues, and high expression of was related to poor survival which can serve as an oncogenic factor and an independent prognostic indicator for glioma patients. Both the GO and GSEA analysis showed high expression of were enriched in Extracellular matrix (ECM) related pathways, the co-expression analysis revealed that was positively related to , , , , , , , , and , and high expression of these genes were also correlated to poor prognosis of glioma.

Conclusions: The results showed that high expression of leads to poor prognosis, and is an independent prognostic factor and a novel biomarker for the treatment of glioma. Furthermore, targeting is most likely a potential therapeutic strategy for glioma patients.